Alvotech (ALVO)
| Previous Close | 11.29 |
| Open | 11.42 |
| Bid | 11.58 x 100 |
| Ask | 11.64 x 100 |
| Day's Range | 11.26 - 11.83 |
| 52 Week Range | 8.29 - 18.00 |
| Volume | |
| Avg. Volume | 121,895 |
| Market Cap | 3.5B |
| Beta (5Y Monthly) | -0.08 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.08 |
| Earnings Date | Aug 27, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.00 |
GlobeNewswireSTADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe Launch of European-made Uzpruvo in Europe comes immediately upon expiry of exclusivity rights for the molecule used to treat certain conditions in gastroenterology1, dermatology and rheumatologyCreates competition at earliest opportunity, enabling straightforward switching to broaden patient access and control costs in a growing market, with accessible indications currently estimated at approxi
- GlobeNewswire
Alvotech Announces Closing of Private Debt Financing
REYKJAVIK, Iceland, July 11, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing of its previously announced senior secured first lien term loan facility (the “Facility”). The closing has allowed Alvotech to refinance outstanding debt obligations, reduce the cost of capital and improve its overall debt maturity profile. Following the closing of the Fa
- GlobeNewswire
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability of AVT03 to Prolia and Xgeva, respectively, have also met their primary endpointAlvotech expects to file marketing applications for AVT03 later this year for major global markets Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines f
